100
Participants
Start Date
February 22, 2021
Primary Completion Date
October 31, 2024
Study Completion Date
January 31, 2025
Tildacerfont/Placebo
Tablet, administered daily
Spruce Study Site, Brisbane
Spruce Study Site, Philadelphia
Spruce Study Site, Philadelphia
Spruce Study Site, Philadelphia
Spruce Study Site, Baltimore
Spruce Study Site, Columbia
Spruce Study Site, Birmingham
Spruce Study Site, Columbus
Spruce Study Site, Cleveland
Spruce Study Site, Canton
Spruce Study Site, Cincinnati
Spruce Study Site, Indianapolis
Spruce Biosciences Clinical Site, Ann Arbor
Spruce Study Site, Minneapolis
Spruce Study Site, Fort Worth
Spruce Study Site, Los Angeles
Spruce Study Site, San Diego
Spruce Study Site, New Brunswick
Spruce Study Site, Providence
Spruce Study Site, Blacktown
Spruce Study Site, Elizabeth Vale
Spruce Study Site, Parkville
Spruce Study Site, Curitiba
Spruce Study Site, São Paulo
Spruce Study Site, Ottawa
Spruce Study Site, Tallinn
Spruce Study Site, Tartu
Spruce Study Site, Munich
Spruce Study Site, Roma
Spruce Study Site, Riga
Spruce Study Site, Kaunas
Spruce Study Site, Krakow
Spruce Study Site, Warsaw
Spruce Study Site, Bucharest
Spruce Study Site, Seoul
Spruce Study Site, Barcelona
Spruce Study Site, Madrid
Spruce Study Site, Seville
Spruce Study Site, Tarragona
Spruce Study Site, Stockholm
Spruce Study Site, Istanbul
Spruce Study Site, Sherbrooke
Spruce Study Site, Birmingham
Lead Sponsor
Spruce Biosciences
INDUSTRY